news
BMS in-licensed PKC theta inhibitor enters clinical trials
A potentially first-in-class PKC theta inhibitor, in development for immunology and inflammation indications, has entered first-in-human trials in the US.
List view / Grid view
Exscientia
news
2021 a record year for investment in UK biotech
New data from the BioIndustry Association (BIA) and Clarivate has shown an increase of 60 percent, to £4.5bn in UK biotech funding in 2021, which is largely the result of overseas investment.
news
First AI designed Alzheimer’s drug to enter clinical trials
The trial of DSP-0038, an Alzheimer’s disease psychosis drug designed using artificial intelligence, will assess its ability to improve the behavioural and psychological symptoms of dementia.
news
First AI-designed immuno-oncology drug enters human trials
The A2a receptor antagonist, which aims to inhibit the immunosuppression of T cells by adenosine, was in part designed using Exscientia’s 3D evolutionary artificial intelligence platform.
news
DSP-1181: drug created using AI enters clinical trials
The developers of DSP-1181, a drug created using AI, announced that it has entered a Phase I clinical trial for the treatment of obsessive-compulsive disorder (OCD).
